Role of medical therapyfor preventing malignant changes in high risk molar pregnancy
Phase 3
- Conditions
- Health Condition 1: null- Patients with high risk molar pregnancy
- Registration Number
- CTRI/2017/09/009723
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
60 patients with pelvic ultrasound showing complete mole having serum beta human chorionic gonadotrophin more than 100000 IU/L,uterine size larger for dates,presence of bilateral theca lutein cysts
Exclusion Criteria
partial mole,histological evidence of chorio ca,previous history of molar pregnancy,total leucocyte count less than 2500/mm3,neutrophil count less than 1500/mm3,SGOT more than 50IU/ml
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method effect of methotrexate on duration of normalisation and regression pattern of serum beta hcgTimepoint: with in 8 weeks of evacuation
- Secondary Outcome Measures
Name Time Method Incidence of GTD in patients receiving chemoprophylaxisTimepoint: serum beta hcg more than 20,000mIU/ml after 4 weeks of evacuation,raised beta hcg after 6 months of evacuation